A Phase 2 interventional study of avatrombopag and Placebo in Thrombocytopenia Associated With Chronic Liver Disease, sponsored by Eisai Co., Ltd.. Completed at 14 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-02-28.
Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.
Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 15th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 6th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 6 · Phase 4 4
First in 2009; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 50 across the 23 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Eisai Co., Ltd. has 6 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing avatrombopag in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease. This study will assess the effect of avatrombopag on platelet counts in Japanese subjects. Subjects will be enrolled into 2 cohorts according to the mean platelet count measured at Screening and Baseline. Within the lower baseline platelet count cohort (less than 40 x 10\^9/L), subjects will be randomized in a 1:1:1:3 ratio to receive placebo, 20 mg avatrombopag, 40 mg avatrombopag, or 60 mg avatrombopag for 5 days. Within the higher baseline platelet count cohort (from 40 to less than 50 x 10\^9/L), subjects will be randomized in a 2:1:2 ratio to receive placebo, 20 mg avatrombopag, or 40 mg avatrombopag for 5 days.
This study will consist of Prerandomization Phase and Randomization Phase. The Prerandomization Phase includes a Screening Period (Day -28 to Day -1) and a Baseline Period (Day 1). During the Prerandomization Phase, participants will be divided into two cohorts based on the platelet count: Low Platelet Count Cohort and High Platelet Count Cohort. Participants in Low Platelet Count Cohort will be randomized to receive one of the four treatments: Placebo, Avatrombopag 20 mg, Avatrombopag 40 mg, or Avatrombopag 60 mg. Participants in High Platelet Count Cohort will be randomized to receive one of the three treatments: Placebo, Avatrombopag 20 mg, or Avatrombopag 40 mg.
The Randomization Phase includes the Treatment Period and the Follow-up Period. The Follow-up Period comprises 3 visits: Visit 4 (5 to 8 days after last dose of study drug [Study Day 10 to 13]), Visit 5 (12 to 15 days after last dose of study drug [Study Day 17 to 20]), and 30 days after receiving the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
Drug: avatrombopag
40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
Drug: avatrombopag
60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
Drug: avatrombopag
Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
Drug: Placebo
E5501 (avatrombopag) 20-mg tablets
Placebo matching 20-mg tablets
Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4
Responders were defined as participants whose platelet count was greater than or equal to 50×10\^9/liter (L) and change from baseline was at least 20×10\^9/L at Visit 4. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% confidence interval (CI) is calculated by Clopper and Pearson method.
Time frame: Baseline and Visit 4 (Day 10)
Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Each Visit
Responders were defined as the participants whose platelet count greater than or equal to 50 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.
Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Percentage of Participants With Platelet Count Greater Than or Equal to 75 x 10^9/L at Each Visit
Responders were defined as the participants whose platelet count greater than or equal to 75 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.
Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Percentage of Participants With Platelet Count Greater Than or Equal to 150 x 10^9/L At Each Visit
Responders were defined as the participants whose platelet count greater than or equal to 150 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.
Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Percentage of Participants With Platelet Count Greater Than or Equal to 200 x 10^9/L At Each Visit
Responders were defined as the participants whose platelet count greater than or equal to 200 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.
Time frame: Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Platelet Count and Change From Baseline in Platelet Count by Visit
Time frame: Baseline, Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety assessments consisted of monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms; physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. A treatment-emergent adverse event (TEAE) was defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. For each category, a participant with two or more adverse events in that category was counted only once. Treatment-related TEAEs were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality.
Time frame: From the date of first dose of study drug up to 30 days after the last dose of the study drug, up to approximately 10 months
Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Value (TEMAV) for Haematology
Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Number of Participants With Clinically Significant Findings in Laboratory Values for Serum
Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Number of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis
Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values
Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
Number of Participants With Markedly Abnormal Electrocardiographs
Time frame: From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months)
| Milestone | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Started | 11 | 7 | 11 | 10 |
| Completed | 11 | 7 | 11 | 10 |
| Not completed | 0 | 0 | 0 | 0 |
Responders were defined as participants whose platelet count was greater than or equal to 50×10\^9/liter (L) and change from baseline was at least 20×10\^9/L at Visit 4. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% confidence interval (CI) is calculated by Clopper and Pearson method.
| Percentage of participants | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4 | 9.1 (0.2 to 41.3) | 28.6 (3.7 to 71.0) | 63.6 (30.8 to 89.1) | 40.0 (12.2 to 73.8) |
Responders were defined as the participants whose platelet count greater than or equal to 50 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.
| Percentage of participants | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Visit 3 (Day 4 or Day 5) | 0.0 (0.0 to 28.5) | 14.3 (0.4 to 57.9) | 27.3 (6.0 to 61.0) | 0.0 (0.0 to 30.8) |
| Visit 4 (Day 10) | 9.1 (0.2 to 41.3) | 71.4 (29.0 to 96.3) | 81.8 (48.2 to 97.7) | 50.0 (18.7 to 81.3) |
| Visit 5 (Day 17) | 27.3 (6.0 to 61.0) | 0.0 (0.0 to 41.0) | 54.5 (23.4 to 83.3) | 20.0 (2.5 to 55.6) |
| Visit 6 (Day 35) | 18.2 (2.3 to 51.8) | 0.0 (0.0 to 41.0) | 9.1 (0.2 to 41.3) | 0.0 (0.0 to 30.8) |
Responders were defined as the participants whose platelet count greater than or equal to 75 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method.
| Percentage of participants | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Visit 3 (Day 4 or Day 5) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 30.8) |
| Visit 4 (Day 10) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 41.0) | 63.6 (30.8 to 89.1) | 30.0 (6.7 to 65.2) |
| Visit 5 (Day 17) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 28.5) | 10.0 (0.3 to 44.5) |
| Visit 6 (Day 35) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 30.8) |
Responders were defined as the participants whose platelet count greater than or equal to 150 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.
| Percentage of participants | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Visit 3 (Day 4 or Day 5) | 0.0 | 0.0 | 0.0 | 0.0 |
| Visit 4 (Day 10) | 0.0 | 0.0 | 0.0 | 0.0 |
| Visit 5 (Day 17) | 0.0 | 0.0 | 0.0 | 0.0 |
| Visit 6 (Day 35) | 0.0 | 0.0 | 0.0 | 0.0 |
Responders were defined as the participants whose platelet count greater than or equal to 200 x 10\^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis.
| Percentage of participants | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Visit 3 (Day 4 or Day 5) | 0.0 | 0.0 | 0.0 | 0.0 |
| Visit 4 (Day 10) | 0.0 | 0.0 | 0.0 | 0.0 |
| Visit 5 (Day 17) | 0.0 | 0.0 | 0.0 | 0.0 |
| Visit 6 (Day 35) | 0.0 | 0.0 | 0.0 | 0.0 |
| Number of platelets x 10^9/L | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Visit 2 (Baseline) Platelet count | 40.59 ± 7.024 | 40.57 ± 5.556 | 41.23 ± 5.159 | 28.85 ± 7.568 |
| Visit 3 (Day 4 or Day 5) Platelet count | 41.27 ± 8.344 | 44.71 ± 6.102 | 46.09 ± 8.860 | 32.70 ± 9.967 |
| Visit 3 (Day 4 or Day 5) Change from baseline | 0.68 ± 2.848 | 4.14 ± 7.099 | 4.86 ± 6.569 | 3.85 ± 6.223 |
| Visit 4 (Day 10) Platelet count | 43.91 ± 10.568 | 53.29 ± 5.678 | 79.36 ± 24.800 | 55.90 ± 22.507 |
| Visit 4 (Day 10) Change from baseline | 3.32 ± 7.163 | 12.71 ± 9.486 | 38.14 ± 22.781 | 27.05 ± 22.700 |
| Visit 5 (Day 17) Platelet count | 40.10 ± 9.916 | 41.33 ± 4.803 | 55.73 ± 14.826 | 41.80 ± 16.578 |
| Visit 5 (Day 17) Change from baseline | 0.40 ± 5.243 | 1.75 ± 3.402 | 14.50 ± 11.874 | 12.95 ± 12.857 |
| Visit 6 (Day 35) Platelet count | 41.50 ± 10.845 | 39.67 ± 5.574 | 41.36 ± 8.262 | 31.44 ± 8.353 |
| Visit 6 (Day 35) Change from baseline | 1.80 ± 4.614 | 0.08 ± 1.686 | 0.14 ± 8.382 | 2.33 ± 4.265 |
Safety assessments consisted of monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms; physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. A treatment-emergent adverse event (TEAE) was defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. For each category, a participant with two or more adverse events in that category was counted only once. Treatment-related TEAEs were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality.
| Participants | Placebo | Avatrombopag 20-mg | Avatrombopag 40-mg | Avatrombopag 60-mg |
|---|---|---|---|---|
| All TEAEs | 8 | 4 | 8 | 3 |
| Treatment-related TEAEs | 0 | 2 | 2 | 0 |
| Serious TEAEs | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug dose adjustment | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug withdrawal | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug dose reduction | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug dose interruption | 0 | 0 | 0 | 0 |
| Participants | Placebo | Avatrombopag 20-mg | Avatrombopag 40-mg | Avatrombopag 60-mg |
|---|---|---|---|---|
| Hemoglobin | 1 | 0 | 0 | 1 |
| Leukocytes | 4 | 4 | 2 | 0 |
| Alkaline phosphatase (ALP) | 1 | 0 | 0 | 0 |
| Alanine aminotransferase (ALT) | 0 | 0 | 0 | 1 |
| Bilirubin | 1 | 1 | 2 | 2 |
| Gamma-glutamyl transferase (γ-GTP) | 0 | 0 | 0 | 1 |
| Calcium | 0 | 0 | 0 | 2 |
| Albumin | 1 | 1 | 1 | 0 |
| Glucose | 3 | 2 | 2 | 1 |
| Triglycerides | 9 | 0 | 1 | 0 |
| Aspartate aminotransferase (AST) | 0 | 1 | 0 | 1 |
| Participants | Placebo | Avatrombopag 20-mg | Avatrombopag 40-mg | Avatrombopag 60-mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Findings in Laboratory Values for Serum | 0 | 0 | 0 | 0 |
| Participants | Placebo | Avatrombopag 20-mg | Avatrombopag 40-mg | Avatrombopag 60-mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis | 0 | 0 | 0 | 0 |
| Participants | Placebo | Avatrombopag 20-mg | Avatrombopag 40-mg | Avatrombopag 60-mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values | 0 | 0 | 0 | 0 |
| Participants | Placebo | Avatrombopag 20-mg | Avatrombopag 40-mg | Avatrombopag 60-mg |
|---|---|---|---|---|
| Number of Participants With Markedly Abnormal Electrocardiographs | 0 | 0 | 0 | 0 |
Collected over From the date of first dose of study drug up to 30 days after the last dose of the study drug, up to approximately 10 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (60 mg) | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Avatrombopag (20 mg) | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Avatrombopag (40 mg) | 0/11 (0%) | 0/11 (0%) | 8/11 (72.7%) |
| Avatrombopag (60 mg) | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) |
|---|---|---|---|---|
| Post Procedural ComplicationInjury, poisoning and procedural complications | 1/11 | 2/7 | 2/11 | 0/10 |
| ConstipationGastrointestinal disorders | 0/11 | 0/7 | 2/11 | 0/10 |
| Post Embolisation SyndromeInjury, poisoning and procedural complications | 0/11 | 0/7 | 2/11 | 1/10 |
| Conjunctival HaemorrhageEye disorders | 0/11 | 1/7 | 0/11 | 0/10 |
| Abdominal DiscomfortGastrointestinal disorders | 1/11 | 1/7 | 0/11 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 1/7 | 0/11 | 1/10 |
| Injection Site ReactionGeneral disorders | 0/11 | 1/7 | 0/11 | 0/10 |
| Vessel Puncture Site HaematomaGeneral disorders | 0/11 | 1/7 | 0/11 | 0/10 |
| Acute SinusitisInfections and infestations | 0/11 | 1/7 | 0/11 | 0/10 |
| Alanine Aminotransferase IncreasedInvestigations | 0/11 | 1/7 | 0/11 | 0/10 |
Full Analysis Set (FAS): The FAS was the group of randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) | Total |
|---|---|---|---|---|---|
| Mean | 71.1 ± 8.49 | 64.6 ± 8.42 | 64.6 ± 9.59 | 62.1 ± 7.32 | 65.8 ± 8.92 |
| Sex: Female, Male(Participants) | Placebo (60 mg) | Avatrombopag (20 mg) | Avatrombopag (40 mg) | Avatrombopag (60 mg) | Total |
|---|---|---|---|---|---|
| Female | 4 | 1 | 5 | 3 | 13 |
| Male | 7 | 6 | 6 | 7 | 26 |
Ran from Jul 2014 to primary completion in Apr 2015, 9 months.
Results were first posted in Feb 2019, 3 years 10 months after primary completion.
Of 54 phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag